candidiasis
CANDIDIASIS
Candida sp are the most common cause of fungal infections.
 It can cause infections that range from benign mucocutaneous illnesses to invasive process that may affect any organ.
 It is considered as normal flora in the gastrointestinal and genitourinary tracts, but when there is an imbalance in the ecological niche, they can invade and cause disease.
Most common risk factors include broad-spectrum antibiotic use, central venous catheter use, receipt of parenteral nutrition, receipt of renal placement therapy by patients in ICUs, neutropenia, implantable prosthetic device use and receipt of immunosuppressive agents.
Drug Information

Indication: Invasive candidiasis, including candidemia in adults.

Indication: Invasive aspergillosis; fluconazole-resistant serious invasive Candida infections (eg, C krusei); serious...

Indication: For adult & childn ≥12 mth: Empirical therapy for presumed fungal infections in febrile, neutropenic pa...

Indication: Relief of external thrush symptoms.

Indication: Candida spp skin infections in which inflammatory symptoms are prominent. Mycotic affections w/ bacterial supe...

Indication: Dermatophytoses, mycoses & various fungi, pityriasis versicolor, infection & superinfection (gm +ve). ...

Indication: Oropharyngeal cavity & GIT candidosis in adults & ped >6 mth.

Endix
econazole nitrate + triamcinolone acetonide

Indication: Dermatophytosis: Tinea pedis, tinea corporis, tinea capitis, tinea cruris, tinea barbae. Tinea versicolor, can...

Indication: Invasive candidiasis in childn & adults. Oesophageal candidiasis in adults, adolescents ≥16 yr & el...

Indication: Topical treatment of dermatophyte skin infections eg, tinea corporis, tinea cruris, tinea manus & tinea pe...

1  /  12
Editor's Recommendations
Most Read Articles
Tristan Manalac, 16 Jul 2019
Caffeinated drinks, such as coffee and black tea, may protect against nonmelanoma skin cancer (NMSC) among Chinese in Singapore, according to a recent study.
6 days ago
New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.